Immix Biopharma, Inc. (IMMX)
$1.82
Rating:
Recommendation:
-
| Symbol | IMMX |
|---|---|
| Price | $1.82 |
| Beta | 0.000 |
| Volume Avg. | 0.20M |
| Market Cap | 25.347M |
| Shares () | - |
| 52 Week Range | 0.68-3.45 |
| 1y Target Est | - |
| DCF Unlevered | IMMX DCF -> | |
|---|---|---|
| DCF Levered | IMMX LDCF -> | |
| ROE | -134550.49% | Strong Sell |
| ROA | -140200.35% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 3.86% | Neutral |
| P/E | -1.03 | Sell |
| P/B | 1.51 | Strong Buy |
Latest IMMX news
About
Download (Excel)Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.